Onclive Team

The International Association for the Study of Lung Cancer (IASLC) announced it is naming the Translational Research Lectureship Award after longtime member and former IASLC CEO, Fred R. Hirsch, MD, PhD, Executive Director of the Center for Thoracic Oncology and Associate Director of Biomarker Discovery at The Tisch Cancer Institute at Mount Sinai and the Joe Lowe and Louis Price Professor of Medicine (Hematology and Medical Oncology) at the Icahn School of Medicine at Mount Sinai.

Noopur Raje, MD, discusses the investigational CAR T-cell therapies and strategies in the multiple myeloma pipeline.

Combining nivolumab (Opdivo) with sitravatinib induced a confirmed objective response rate of 39% and a 92% clinical benefit rate in patients with advanced clear cell renal cell carcinoma.

The oral hypoxia-inducible factor-2α inhibitor MK-6482 induced a partial response rate of 24% and a disease control rate of 80% in patients with advanced clear cell renal cell carcinoma.

Combination therapy with radium-223 and sipuleucel-T yielded conflicting results in patients with metastatic castration-resistant prostate cancer.

Rush is the only Illinois hospital to receive this National Pancreatic Foundation designation.

The Association of Community Cancer Centers is pleased to announce that its Multidisciplinary Chronic Lymphocytic Leukemia Care education project is conducting a series of quality improvement workshops to promote the optimal care and management of patients diagnosed with chronic lymphocytic leukemia.

For years, the treatment landscape for bladder cancer was defined by lackluster consistency: There were no advances. However, the drought ended with the introduction of immune checkpoint blockade, according to Charles G. Drake, MD, PhD.

After more than 30 years of leadership as chair of City of Hope’s Department of Hematology & Hematopoietic Cell Transplantation, Stephen J. Forman, MD, has decided to transition out of this role.

Therapeutic developments in cancer were rewarded with a wave of approvals in 2019.

Investigators at John Theurer Cancer Center at Hackensack University Medical Center in New Jersey are the first to report poor adherence to genomic profiling guidelines for four biomarkers of metastatic colorectal cancer used to predict response to therapy, choose the most effective treatment, and improve outcomes — showing that only 40% of patients had their tumors tested.

The Association of Community Cancer Centers congratulates the entire oncology community on the achievement of the largest one-year drop in cancer mortality—the record decline in annual cancer deaths was measured from 2016 to 2017.

Investigators at John Theurer Cancer Center at Hackensack University Medical Center in New Jersey were part of the CANDOR global phase III clinical trial for patients with refractory multiple myeloma.

Five new physicians have joined the medical staff at John Theurer Cancer Center at Hackensack University Cancer Center in New Jersey.

The addition of brentuximab vedotin to standard 3-drug chemotherapy for patients with newly diagnosed, advanced-stage classical Hodgkin lymphoma continued to outperform a 4-drug chemotherapy standard.

IMGN632, an investigational anti-CD123 antibody-drug conjugate, demonstrated preliminary activity in patients with relapsed/refractory acute myelogenous leukemia or blastic plasmacytoid dendritic cell neoplasm.

The investigational Bruton tyrosine kinase inhibitor ARQ 531 demonstrated safety and clinical activity across a range of B-cell malignancies.

Patients with premenopausal breast cancer and discordant clinical and genomic risk had a small increase in distant metastasis if they did not receive adjuvant chemotherapy, according to a post hoc analysis of the MINDACT trial.

Almost half of patients with high-risk luminal-B breast cancer converted to a low risk of recurrence following chemotherapy-free neoadjuvant therapy, matching the performance of standard chemotherapy in small randomized trial.

A subcutaneous fixed-dose combination of pertuzumab and trastuzumab demonstrated noninferiority to intravenous formulations of the 2 drugs with respect to pharmacokinetics, clinical activity, and safety, a randomized trial demonstrated.

Subcutaneous trastuzumab with hyaluronidase-oysk in combination with intravenous pertuzumab and chemotherapy had a safety profile consistent with IV trastuzumab in first-line metastatic HER2-positive breast cancer treatment.

A pathologic complete response to HER2-directed neoadjuvant therapy reduced the risk of recurrence in early HER2-positive breast cancer but did not eliminate it, supporting the common practice of continued anti-HER2 therapy.

The first reported data for adjuvant ado-trastuzumab emtansine in early HER2-positive breast cancer showed high rates of disease control in a randomized trial designed to compare toxicities with trastuzumab and paclitaxel.

More than three times as many patients with transplant-ineligible newly diagnosed multiple myeloma remained alive and progression free after >3 years when they received daratumumab (Darzalex) in addition to standard first-line therapy.

Adding an anti-CD38 antibody to a 3-drug chemotherapy-free regimen led to deeper and more frequent responses in patients with transplant-eligible, newly diagnosed multiple myeloma.

Patients with relapsed/refractory chronic lymphocytic leukemia had ongoing benefits 42 months after starting treatment with the BTK inhibitor acalabrutinib.

In patients with relapsed mantle cell lymphoma, treatment with ibrutinib might mitigate a historical trend toward decreased progression-free survival with succeeding lines of therapy.

The combination of polatuzumab-vedotin (Polivy), obinutuzumab (Gazyva), and lenalidomide (Revlimid) induced a high rate of durable responses in patients with relapsed/refractory follicular lymphoma.